Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002704 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
A Phase 2 study of Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT00002704: Completed Phase 2 study of Leukemia, sponsored by National Cancer Institute (NCI).
NCT00002704 is a Phase 2 study of Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 156 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002704, a Phase 2 study of Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- University of California San Diego Cancer Center - La Jolla
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- University of California Davis Medical Center - Sacramento
- Children's Hospital and Health Center - San Diego
Florida
- Shands Hospital and Clinics, University of Florida - Gainesville
- Sylvester Cancer Center, University of Miami - Miami
- Miami Children's Hospital - Miami
- CCOP - Florida Pediatric - Tampa
Kansas
- University of Kansas Medical Center - Kansas City
- CCOP - Wichita - Wichita
- Via Christi Regional Medical Center - Wichita
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
- MBCCOP - University of South Alabama - Mobile
Louisiana
- MBCCOP - LSU Medical Center - New Orleans
- Tulane University School of Medicine - New Orleans
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Yale Comprehensive Cancer Center - New Haven
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 1996-01 |
| Phase | Phase 2 |
What the finished NCT00002704 record still lists
NCT00002704 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002704 names 20 study sites across 10 states, led by California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT00002704 about?
NCT00002704 is a clinical study titled "Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia". Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with rad...
What is the current status of trial NCT00002704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 1996-01.
What conditions does trial NCT00002704 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00002704?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), filgrastim (BIOLOGICAL), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002704?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002704 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002704's enrollment target sits among peer trials
156 47th of 233 higher than 187 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia